Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.

Huynh E, Sigal D, Saven A

Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia.

Martin FM, Prchal J, Nieva J, Saven A, Andrey J, Bethel K, Barton JC, Aripally G, Bottomley SS, Friedman JS

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH

Cladribine in indolent non-Hodgkin's lymphoma.

Sigal DS, Saven A

Hairy cell leukemia.

Fanta PT, Saven A

Understanding hairy cell leukemia genetics.

Nieva J, Saven A

How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma?

Diamond C, Taylor TH, Im T, Wallace M, Saven A, Anton-Culver H

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD, Cancer and Leukemia Group B Study 9153

Cladribine in hairy cell leukemia.

Belani R, Saven A

Use of optophoresis as an in vitro predictor of cell response to chemotherapy for chronic lymphocytic leukemia.

Nerenberg M, Kariv I, McNeeley P, Marchand P, Sur S, Diver J, Riccitelli S, Nieva J, Saven A